Table 1 Demography of patients with Parkinson’s disease.

From: Platelet abnormalities in patients with Parkinson's disease undergoing preoperative evaluation for deep brain stimulation

Characteristics

PD patients (n = 106)

Age (years)

35–77 (62.5 ± 7.4)

Sex (Female : Male)

51:55

Duration of symptoms (years)

5–37 (11.7 ± 5.4)

Hoehn and Yahr stage

 

Off

2–5 (3.6 ± 0.6)

On

1–5 (2.5 ± 0.7)

UPDRS-III

Off

16–95 (41.4 ± 12.5)

On

3–40 (18.7 ± 8.7)

PT (second)

9.3–11.5 (10.3 ± 0.5)

aPTT (second)

22.2–32.6 (27.6 ± 2.0)

Levodopa (mg/day)

150–2400 (865.7 ± 383.8)

LEDD (mg/day)

165–2805 (1341.4 ± 501.0)

PD medications

Levodopa/benserazide

74 (69.8%)

Entacapone

56 (52.8%)

Amantadine

56 (52.8%)

Carbidoma/levodopa

48 (45.3%)

Pramipexole

45 (42.5%)

Ropinirole

32 (30.2%)

Biperiden

23 (21.7%)

Rotigotine

14 (13.2%)

Selegiline

9 (8.5%)

  1. PD, Parkinson’s disease; UPDRS, Unified Parkinson’s Disease Rating Scale; PT, prothrombin time; aPTT, activated partial prothrombin time; LEDD, levodopa equivalent daily dose.
Back to article page